ReviewNature microbiology2020
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies.
Review in Nature microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 429 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
429 citing papers in PubMed, 2 syntheses or guidelines pooled it, 715 citations in OpenAlex.
- Research hotspots and global trends in respiratory syncytial virus over past five years.Frontiers in microbiology · 2025Pooled it
- SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.The Cochrane database of systematic reviews · 2022Pooled it
- Trial
- Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season.Journal of the Pediatric Infectious Diseases Society · 2024Trial
- Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency.Nature communications · 2023Trial
- Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19: A phase 2a, open-label, single-dose escalation study.British journal of clinical pharmacology · 2023Trial
- Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.The Lancet. Infectious diseases · 2022Trial
- Trial
- Mechanisms of antibody-dependent enhancement and its research progress in animal coronaviruses.Veterinary research · 2026Review
- Pre-vaccine sentinel antibodies predict blunted vaccine responses.Cell press blue · 2026Article
- Reverse genetics strategies for coronaviruses: platform construction and applications in vaccine development.Virus genes · 2026Review
- Neutralizing nanobodies against porcine epidemic diarrhea virus: discovery and characterization.BMC veterinary research · 2026Article
- Article
- Occurrence of Antibody-Dependent Enhancement of Avian Infectious Bronchitis in Target Animal Experiments.Veterinary sciences · 2026Article
- A novel dual-target fusion vaccine simultaneously targeting WFBI and WFBII components elicits synergistic protection against Eimeria necatrix.Poultry science · 2026Article
- Building better antibody responses: The interplay of infection, vaccination, and immune imprinting.PNAS nexus · 2026Review
- Epitranscriptomic signatures of m5C, m6A, and pseudouridine in COVID-19 reveal host RNA modifications involved in viral pathogenesis.Microbiology spectrum · 2026Article
- Long COVID: a review of mechanisms and treatment modalities.Inflammopharmacology · 2026Review
- Co-infection of SARS-CoV-2 and DENV case report in Jazan Region Southwest Saudi Arabia.BMC infectious diseases · 2026Article
- Fc-mediated antibody functions are associated with disease severity in COVID-19.Frontiers in immunology · 2026Article
369 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data from the study of SARS-CoV and other respiratory viruses suggest that anti-SARS-CoV-2 antibodies could exacerbate COVID-19 through antibody-dependent enhancement (ADE). Previous respiratory syncytial virus and dengue virus vaccine studies revealed human clinical safety risks related to ADE, resulting in failed vaccine trials. Here, we describe key ADE mechanisms and discuss mitigation strategies for SARS-CoV-2 vaccines and therapies in development. We also outline recently published data to evaluate the risks and opportunities for antibody-based protection against SARS-CoV-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.